Experimental Drug Slashes Triglycerides By 70% in Study
(HealthDay News) — An experimental drug, ISIS 304801, can lower triglyceride levels by as much as 71%, according to study results published in the July 30 issue of the New England Journal of Medicine.
Joseph Witztum, MD, a professor of medicine at the University of California, San Diego, and colleagues treated 57 patients with the drug or an inactive placebo. The patients' triglyceride levels ranged between 350–2,000mg/dL, and they received weekly doses of the drug over 13 weeks. The study also included 28 people who had triglyceride levels ranging from 225–2,000mg/dL, who had been receiving fibrate therapy. These patients also received the new drug or placebo.
Overall, the researchers found that ISIS 304801 reduced triglyceride levels 31–71%. No safety concerns were identified.
This trial was the second of three required for drug approval in the United States. Witztum told HealthDay that phase 3 trials are underway, but the results will not be available for two to three years.
The study was funded by Isis Pharmaceuticals, the manufacturer of ISIS 304801.